ACAD logo

ACADIA Pharmaceuticals (ACAD) Company Overview

Profile

Full Name:

ACADIA Pharmaceuticals Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

May 27, 2004

Indexes:

Not included

Website:

http://www.acadia.com

Description:

ACADIA Pharmaceuticals Inc. is an American biopharmaceutical company headquartered in San Diego, California, focused on the development and commercialization of innovative drugs for patients with central nervous system disorders. It was founded in 1993 as Receptor Technologies, Inc. The company commercializes the drug NUPLAZID (Pimavanserin), which was approved by the U.S. Food and Drug Administration (FDA) in April 2016 for the treatment of psychosis in Parkinson's disease (PD psychosis) and is the first and only drug approved in the U.S. for this condition. Additionally, the company continues to study the use of the drug for the treatment of other neurological and psychiatric disorders.

Key Details

Price

$19.36

Market Cap

$3.22 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$726.44 M(+40.45% YoY)

Annual EPS

-$0.37(+72.39% YoY)

PE Ratio

24.82

Annual ROE

-14.73%

Annual Debt To Equity

0.00

Beta

0.86

Events Calendar

Earnings

Next earnings date:

May 8, 2025

Recent quarterly earnings:

Feb 26, 2025

Recent annual earnings:

Feb 26, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 11, 25 Deutsche Bank
Hold
Jan 3, 25 Guggenheim
Neutral
Nov 7, 24 Needham
Buy
Nov 7, 24 HC Wainwright & Co.
Buy
Aug 8, 24 UBS
Buy
Aug 8, 24 HC Wainwright & Co.
Buy
Aug 8, 24 Citigroup
Buy
Aug 7, 24 RBC Capital
Outperform
Aug 7, 24 Needham
Buy
Aug 7, 24 Morgan Stanley
Equal-Weight

Screeners with ACAD included

Growing Shares Outstanding
Mid cap stocks
US stocks
High Piotroski score stocks
Earnings this week
Most recommended stocks
Best performing stocks last 3 months
Stocks above SMA 50
Stocks below analysts price target
Healthcare sector

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$19.36
ACAD price is $19.36

Price All-time High

$57.00
ACAD price is currently -66.04% below its historical high of $57.00

Price Analysts Target

$25.00
ACAD price is currently -22.56% lower than the consensus analysts' forecast

Price Today Change

+1.89%
ACAD price is up +1.89% today

Price YTD Change

+4.48%
ACAD price is up +4.48% since January 1st

Price 3-Year Change

-23.81%
ACAD price is down -23.81% over the past 3 years

Market cap

Market Cap

$3.22 B
ACAD market capitalization is $3.22 billion

Market Cap 3-Year Change

-21.42%
ACAD market capitalization is down -21.42% over the past 3 years

Market Cap All-time High

$9.03 B
ACAD market capitalization is currently -64.32% below its historical high of $9.03 billion

Market Cap Sector Rank

85.54%
ACAD market capitalization is higher than 85.54% of companies in Healthcare sector

Technical

Beta

0.86
ACAD beta is 0.86

200-day SMA

$16.65
ACAD price is currently +16.28% above its 200-day simple moving average

14-day RSI

56.07
ACAD 14-day relative strength index is 56.07

30-day Relative Volume

0.84
ACAD 30-day relative volume is 0.84

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$726.44 M
ACAD annual revenue is $726.44 million

Annual Revenue Analysts Estimate

$969.41 M
ACAD annual revenue is currently -25.06% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+40.45%
ACAD annual revenue is up +40.45% year-on-year

Annual Revenue Sector Rank

77.83%
ACAD annual revenue is higher than 77.83% of companies in Healthcare sector

Profit

Annual Gross Profit

$684.80 M
ACAD annual gross profit is $684.80 million

Annual Gross Margin

94.27%
ACAD annual gross profit margin is 94.27%

Annual Operating Profit

-$73.38 M
ACAD annual operating income is -$73.38 million

Annual Operating Margin

-10.10%
ACAD annual operating profit margin is -10.10%

Annual Net Income

-$61.29 M
ACAD annual net profit is -$61.29 million

Annual Net Margin

-8.44%
ACAD annual net profit margin is -8.44%

EPS

Annual EPS

-$0.37
ACAD annual earnings per share is -$0.37

Annual EPS Analysts Estimate

$0.74
ACAD annual earnings per share is currently -150.22% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+72.39%
ACAD annual earnings per share is up +72.39% year-on-year

Annual EPS Sector Rank

74.16%
ACAD annual earnings per share is higher than 74.16% of companies in Healthcare sector

ROA & ROE

Annual ROA

-9.17%
ACAD annual return on assets is -9.17%

Annual ROE

-14.73%
ACAD annual return on equity is -14.73%

EBIT & EBITDA

Annual EBIT

-$73.38 M
ACAD annual earnings before interest & taxes is -$73.38 million

Annual EBITDA

-$67.83 M
ACAD annual EBITDA is -$67.83 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

24.82
ACAD price to earnings ratio is 24.82

PE Ratio Sector Rank

46.32%
ACAD price to earnings ratio is higher than 46.32% of companies in Healthcare sector

PB Ratio

PB Ratio

5.58
ACAD price to book ratio is 5.58

PB Ratio Sector Rank

84.13%
ACAD price to book ratio is higher than 84.13% of companies in Healthcare sector

PS Ratio

PS Ratio

3.47
ACAD price to sales ratio is 3.47

PS Ratio Sector Rank

52.02%
ACAD price to sales ratio is higher than 52.02% of companies in Healthcare sector

Enterprise value

Enterprise Value

$3.12 B
ACAD enterprise value is $3.12 billion

Enterprise Value Sector Rank

85.26%
ACAD enterprise value is higher than 85.26% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

25.02
ACAD EV/EBITDA is 25.02

EV/EBITDA Sector Rank

93.46%
ACAD EV/EBITDA is higher than 93.46% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

2.42
ACAD annual current ratio is 2.42

Annual Quick Ratio

2.28
ACAD annual quick ratio is 2.28

Leverage

Annual Debt To Equity

0.00
ACAD annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
ACAD annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

6
ACAD piotroski f-score is 6

Altman Z-Score

2.78
ACAD altman z-score is 2.78

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$748.96 M
ACAD annual total assets is $748.96 million

Annual Non Current Assets

$132.83 M
ACAD annual long term assets is $132.83 million

Annual Current Assets

$616.13 M
ACAD annual total current assets is $616.13 million

Annual Cash & Cash Equivalents

$188.66 M
ACAD annual cash & cash equivalents is $188.66 million

Equity

Annual Book Value

$431.75 M
ACAD annual book value is $431.75 million

Annual Working Capital

$361.87 M
ACAD annual working capital is $361.87 million

Liabilities

Annual Total Liabilities

$317.20 M
ACAD annual total liabilities is $317.20 million

Annual Total Long Term Liabilities

$62.95 M
ACAD annual total long term liabilities is $62.95 million

Annual Current Liabilities

$254.25 M
ACAD annual total current liabilities is $254.25 million

Annual Accounts Payable

$17.54 M
ACAD annual accounts payable is $17.54 million

Debt

Annual Total Debt

$57.20 M
ACAD annual total debt is $57.20 million

Annual Total Debt 1-Year Change

-7.73%
ACAD annual total debt is down -7.73% year-on-year

Annual Long Term Debt

$47.80 M
ACAD annual long term debt is $47.80 million

Annual Short Term Debt

$9.40 M
ACAD annual short term debt is $9.40 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$799.82 M
ACAD annual total expenses is $799.82 million

Annual Operating Expenses

$758.18 M
ACAD annual total operating expenses is $758.18 million

Annual Cost Of Goods Sold

$41.64 M
ACAD annual cost of goods sold is $41.64 million

Annual SGA

$406.56 M
ACAD annual SGA is $406.56 million

Annual D&A

$5.55 M
ACAD annual depreciation & amortization is $5.55 million

Annual Interest Expense

-
ACAD annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

$16.70 M
ACAD annual cash flow from operations is $16.70 million

Annual CFO 1-Year Change

+114.65%
ACAD annual cash flow from operations is up +114.65% year-on-year

Annual CFI

$32.00 M
ACAD annual cash flow from investing activities is $32.00 million

Annual CFI 1-Year Change

-56.31%
ACAD annual cash flow from investing activities is down -56.31% year-on-year

Annual CFF

$25.13 M
ACAD annual cash flow from financing activities is $25.13 million

Annual CFF 1-Year Change

+206.49%
ACAD annual cash flow from financing activities is up +206.49% year-on-year

Free CashFlow

Annual FCF

-$23.35 M
ACAD annual free cash flow is -$23.35 million

Annual FCF 1-Year Change

+79.53%
ACAD annual free cash flow is up +79.53% year-on-year

CAPEX

Annual CAPEX

$40.05 M
ACAD annual capital expenditures is $40.05 million

Annual CAPEX 1-Year Change

-
ACAD annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

MRUS logo
Merus NV (MRUS)
SGRY logo
Surgery Partners (SGRY)
PRVA logo
Privia Health (PRVA)
VKTX logo
Viking Therapeutics (VKTX)
CRNX logo
Crinetics Pharmaceuticals (CRNX)
HAE logo
Haemonetics (HAE)
ACHC logo
Acadia Healthcare (ACHC)
ACLX logo
Arcellx (ACLX)
RYTM logo
Rhythm Pharmaceuticals (RYTM)

FAQ

  • What is the ticker symbol for ACADIA Pharmaceuticals?
  • Does ACADIA Pharmaceuticals pay dividends?
  • What sector is ACADIA Pharmaceuticals in?
  • What industry is ACADIA Pharmaceuticals in?
  • What country is ACADIA Pharmaceuticals based in?
  • When did ACADIA Pharmaceuticals go public?
  • Is ACADIA Pharmaceuticals in the S&P 500?
  • Is ACADIA Pharmaceuticals in the NASDAQ 100?
  • Is ACADIA Pharmaceuticals in the Dow Jones?
  • When was ACADIA Pharmaceuticals's last earnings report?
  • When does ACADIA Pharmaceuticals report earnings?
  • Should I buy ACADIA Pharmaceuticals stock now?

What is the ticker symbol for ACADIA Pharmaceuticals?

The ticker symbol for ACADIA Pharmaceuticals is NASDAQ:ACAD

Does ACADIA Pharmaceuticals pay dividends?

No, ACADIA Pharmaceuticals does not pay dividends

What sector is ACADIA Pharmaceuticals in?

ACADIA Pharmaceuticals is in the Healthcare sector

What industry is ACADIA Pharmaceuticals in?

ACADIA Pharmaceuticals is in the Biotechnology industry

What country is ACADIA Pharmaceuticals based in?

ACADIA Pharmaceuticals is headquartered in United States

When did ACADIA Pharmaceuticals go public?

ACADIA Pharmaceuticals's initial public offering (IPO) was on May 27, 2004

Is ACADIA Pharmaceuticals in the S&P 500?

No, ACADIA Pharmaceuticals is not included in the S&P 500 index

Is ACADIA Pharmaceuticals in the NASDAQ 100?

No, ACADIA Pharmaceuticals is not included in the NASDAQ 100 index

Is ACADIA Pharmaceuticals in the Dow Jones?

No, ACADIA Pharmaceuticals is not included in the Dow Jones index

When was ACADIA Pharmaceuticals's last earnings report?

ACADIA Pharmaceuticals's most recent earnings report was on Feb 26, 2025

When does ACADIA Pharmaceuticals report earnings?

The next expected earnings date for ACADIA Pharmaceuticals is May 8, 2025

Should I buy ACADIA Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions